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ABSTRACT 
Objective: To formulate and characterize Lorazepam loaded buccal patches using mucoadhesive, biodegradable, natural polymers-pectin 
(hydrophilic) and collagen (lipophilic) for treating epileptic seizures.  
Methods: Lorazepam loaded buccal patches were prepared by solvent casting method and were subjected to various Physico-chemical evaluation 
parameters to find the optimized buccal patch. The in vitro drug release study and ex vivo permeation study was carried out. The stability study and 
histopathological study of optimized Lorazepam loaded buccal patch was also carried out.  
Results: From in vitro drug release study, it was found that Lorazepam loaded buccal patch (B4) exhibited maximum drug release of 96.16 %±0.07 
than other formulations at the end of 4 h, indicating an initial burst release followed by sustained release with release kinetics as Higuchi diffusion 
model. Based on the in vitro drug release, % drug content, % swelling index, folding endurance, B4 formulation was considered as optimised 
formulation and was further characterized. Ex vivo permeation study revealed that the cumulative amount of drug permeated from optimised 
Lorazepam loaded buccal patch (B4) was higher (3831.4±0.21µg/cm2) than marketed Midazolam buccal solution (1724±0.12 µg/cm2) and control 
drug solution (895.42±0.07 µg/cm2) with an enhancement ratio of 4.8. B4 formulation also showed a higher flux value (12.52±0.02µg/cm2/hr) 
compared to marketed formulation (5.732±0.01 µg/cm2) and control drug solution (2.563±0.03 µg/cm2) of P<0.05. The histopathological study 
using bovine buccal mucosa revealed that the B4 formulation is safe for buccal application. The stability study confirmed that B4 formulation is 
stable in both room and refrigeration conditions. Hence the formulated Lorazepam loaded buccal patch seems to be a promising carrier for the 
enhanced buccal delivery of Lorazepam in treating epileptic seizures. 
Conclusion: The formulated Lorazepam loaded collagen/pectin buccal patch was found to be an efficient and stable route for the buccal delivery of 
Lorazepam in treating acute epileptic seizures which could be further explored scientifically. 
Keywords: Lorazepam, Buccal patch, In vitro drug release, Steady-state flux, Epileptic seizures 




Epilepsy is a disorder of the central nervous system, precisely the 
brain, characterized by enduring predisposition and neuronal 
misfiring that ultimately results in epileptic seizures [1]. It causes the 
periodic loss of consciousness with abnormal electrical activity which 
either leads to convulsions or not leads to convulsions [2]. Epileptic 
seizure is an event of transient occurrence of signs and symptoms due 
to hypersynchronous activity of the neurons [3, 4]. Commonly used 
medications for these epileptic seizures include oral dosage forms and 
intravenous dosage forms. These were found to be effective for 
management of chronic the epileptic seizures but were not effective to 
treat acute and immediate seizures [5-6]. Even though there are 
different modes of drug delivery systems all these were not able to 
save the golden hour, the time from the onset of rapid seizure to the 
time the person reaches the hospital [7]. Buccal drug delivery systems 
were found to produce this rapid onset of action as this region is 
immensely supplied with blood vessels and the drug directly reaches 
the systemic circulation surpassing the bypass effect. Among them the 
most effective one was found to buccal/mucosal patches incorporated 
with the drug [8-9]. The drug too should be such that it is adequately 
lipophilic, should possess high molecular weight, should be of low size 
and above all it should have rapid onset of action. All the 
benzodiazepenes category drugs like Midazolam, Diazepam were 
found to be effective all these exhibited several serious side effects 
especially sedation [10, 11]. Therefore the aim of our study was to 
develop a drug delivery system made of natural polymers only and 
that incorporates a rapid-acting antiepileptic drug to resolve all these 
disadvantages and limitations of both the drug delivery system and 
the drug, effective for the management of acute seizures [12-15]. 
MATERIALS AND METHODS 
Materials and excipients 
Lake Chemicals Private Limited, Bangalore gifted us with Lorazeapm 
API. Pectin was obtained from CK’S products, Kochi. Collagen was 
obtained from Nitta Gelatin India ltd, Kochi. Olive oil was obtained 
from Thomson trading agencies, Kochi. All the chemicals used in the 
experiment were of analytical grade [16, 17]. 
Preformulation studies 
Solubility 
The solubility of drug was checked in different solvents such as 
methanol, distilled water, propanol, acetone, phosphate buffer saline 
(PBS) pH 6.8 [18]. 
Melting point 
The melting point of the obtained drug sample indicates the purity 
of the sample. The melting point will be reduced in the presence of 
very few quantities of impurity. The melting point was found using 
open capillary method [19]. 
Partition coefficient 
Partition coefficient of lorazepam in n-octanol was found out. The 
formed aqueous layer and organic phase were separated and the 
distribution of solute in both phase were determined by UV 
spectroscopy at 229 nm [20-23]. 
Drug compatibility with excipients 
Excipients are added to improve the elegance of formulation, assist 
the progress of drug administration and promote bioavailability of 
drug for consistent release and protection from degradation. The 
excipients should be tentatively elected in order to get and 
productive dosage form [24-26]. 
Fourier Transform Infra-Red (FTIR) spectroscopy study 
By FTIR spectrophotometer using KBr pellet method, FTIR spectra 
of drug and excipients were obtained to ascertain the compatibility 
between drug (lorazepam API) and selected polymer [27]. 
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Formulation of Lorazepam loaded collagen/pectin buccal patches 
In this study, lorazeapm loaded buccal patches were prepared by 
solvent casting method using a blend of biodegradable natural 
polymers like pectin (hydrophilic) and collagen (lipophilic) with olive 
oil as permeation enhancer and plasticizer [28]. Patches were 
prepared with a concentration of collagen ranging from 0.25-1.25%, 
the percentage of pectin was kept constant at 1.5% after optimization 
and used 0.05 ml of olive oil. The weighed quantities of pectin and 
collagens were dissolved separately in beakers containing 10 ml 
distilled water [29-31]. 20 mg (2%) of drug was dissolved with olive 
oil and added small quantity of previously prepared collagen solution 
with proper continuous stirring. After complete dissolution of drug, 
remaining collagen solution was added followed by addition of 
pectin solution drop by drop and shaking after each drop to get a 
homogenous mixture. This was kept in a magnetic stirrer for 30 
min at 600rpm. Then the mixture was poured in a Petri dish of size 
5×3 cm2 initially coated with glycerine to avoid sticking of the 
patch [32-35]. The Petri dish was placed in hot air oven at 
temperature 40-45 °C for 24 h to get uniformly dried buccal 
patches. The formulation composition of lorazepam loaded buccal 
patches was shown in table 1. 
 
Table 1: Formulation composition of Lorazeapam loaded collagen/pectin buccal patches 
S. No. Formulation code Lorazepam (%) Pectin (%) Collagen (%) Olive oil (%) Distilled water(ml) 
1. B1 0.4 1.5 1.25 0.005 qs.20 
2. B2 0.4 1.5 1 0.005 qs.20 
3. B3 0.4 1.5 0.75 0.005 qs.20 
4. B4 0.4 1.5 0.5 0.005 qs.20 
5. B5 0.4 1.5 0.25 0.005 qs.20 
 
Preparation of backing membrane 
PVA-aluminium foil backing membrane was prepared by solvent casting 
film technique. It was casted by pouring 4% w/v aqueous solution of 
PVA on aluminum foil in Petri dishes at 42 °C and left for 10hours to 
obtain dry film of drug impermeable backing membrane. The patches of 
suitable size were then cut and stored under suitable condition [36]. 
Physicochemical evaluation of prepared Lorazepam loaded 
buccal patches 
The Physico-chemical evaluation studies of prepared lorazepam 
loaded patches were described below. 
Thickness uniformity of the patches 
Micrometer screw gauge was used to measure the thickness of three 
patches of 2×2 cm2 size of formulation at three different places and 
mean value was determined [37]. 
Uniformity of weight of the patches 
Digital balance was used to determine the weight of three patches of 
every formulation of size 2×2 cm2 and individual weight was noted 
and calculated the average weight [38]. 
Folding endurance 
Determination of folding endurance is by folding strip of patch of 
size 2×2 cm2 at the same place till it broke. The number of time the 
patch could be folded at the same place without breaking gave the 
value of folding endurance [39]. 
Surface pH determination 
Swelling index was determined by allowing three patches of each 
formulation of size 2×2 cm2 to swell by keeping in contact with 1 ml 
of distilled water for 1 hour at room temperature [40]. 
Percentage swelling index 
Three patches of each formulation were cut into 2×2 cm2and 
weighed initially and kept immersed in 50 ml PBS pH 6.8. Taken out 
and weighed at 5, 10, 30 and 60 min time intervals till a constant 
weight was obtained [41]. 
Percentage of moisture absorption 
Physical stability of the patches was evaluated in high humidity 
conditions. Accurately weighed 3 patches were kept in a desicator 
containing aluminium chloride solution for 3 d. The percentage of 
moisture content was determined by reweighing the patches [42]. 
Drug content uniformity 
The drug-loaded patches of known weight 2×2 mm dimension from 
3 different areas were dissolved in 10 ml of methanol and shaken 
until it dissolved. At 229 nm the absorbance of the diluted drug 
solution was measured. The polymer solution without drug served 
as blank [43]. 
In vitro mucoadhesion study 
In vitro mucoadhesion time 
Evaluation of Mucoadhesion properties of lorazepam loaded buccal 
patches was carried out by performing in vitro mucoadhesion study. 
Detachment time of lorazepam loaded buccal patches was 
determined. Initially, bovine buccal mucosa was kept in PBS pH 6.8 
and stored in freezer and room temperature. Fixing of buccal 
mucosa was in such a way that mucosal surface placed in glass slide 
should face towards the the lorazeapm loaded buccal patch of 2×2 
cm2 of each formulation. The above mucosa was then placed in the 
glass beaker containing 100 ml of PBS pH 6.8 and was magnetically 
stirred at 100 rpm. In vitro mucoadhesion time was considered as 
time required for erosion of Lorazepam loaded buccal patches 
visually [44]. 
In vitro mucoadhesive strength  
Specialised chemical balance helps to determine the force or stress 
used for the detachment of per cm square of area of bovine buccal 
mucosa in which the lorazeapm loaded buccal patches placed in 
between mucosae. The buccal mucosae were arranged in such a way 
that on a clear glass surface of one side of balance a section of buccal 
mucosa was tied with help of a rubber band and another mucosa 
placed in inverted position to that of first so that both mucosal 
surfaces face each other. Each formulation of lorazepam loaded buccal 
patch of size 2×2 cm2 was kept in between the two mucosae. 
Measurement of different formulation was noted from different 
mucosae. Mucoadhesive strength was determined from detachment of 
two mucosae by increasing the weight on the other side of pan [45].  
In vitro drug release study 
The in vitro drug release studies of different formulations of 
lorazepam loaded buccal patches were done by static dissolution 
method. The apparatus was set up by introducing an open end tube 
aligned vertically to a beaker containing 50 ml of PBS pH 6.8 which 
acts as receptor compartment. The open end tube was tied with a 
cellophane membrane (molecular weight 12000-14000 D) on one 
side which resembles the membrane acting as a barrier within the 
body, so that only the tip touches the surface of buffer solution. The 
reaction conditions were standardised throughout the study. The 
receptor compartment was filled with 50 ml of PBS 6.8 and the 
donor compartment with 2 cm2 of lorazepam loaded buccal patch. 
The beaker was placed on a magnetic stirrer for a definite study time 
and 1 ml of samples was withdrawn at regular intervals. For each 
withdrawal, 1 ml of fresh PBS pH 6.8 was replaced into the beaker 
and the collected samples were diluted using the same. The 
percentage of drug released in the receptor medium was 
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spectrometrically analysed using UV visible spectrophotometer at 
229 nm. All the analysis was done triplicate [46]. 
Kinetic models of in vitro drug release study 
The data obtained from in vitro release studies of lorazepam buccal 
patches were fitted to various kinetic models such as Zero order, 
First order, Higuchi plot and Koresmeyer-peppas plot to identify the 
model of drug release of lorazepam buccal patches. 
Ex vivo permeation study 
Buccal mucosa preparation 
The bovine buccal mucosal region was collected from a local slaughter 
house at morning and the buccal mucosa was cleaned with normal 
saline and used for the study by noon. The underlying fat deposits 
were initially excised off uniformly and the mucosal membrane was 
separated out. The buccal mucosal layer retaining all the layers was 
allowed to equilibrate for one hour in receptor buffer to retain its 
properties as live tissue. Later on the mucosa was stored in containers 
partly filled with normal saline solution until further use [47]. 
Preparation of set up in franz diffusion cell 
The ex vivo permeation comparison study of optimised lorazepam 
loaded buccal patch (B4), midazolam buccal solution (marketed 
formulation) and control drug solution (drug in buffer pH 6.8 were 
done in franz diffusion cell having a donar and receptor 
compartment in it. The receptor compartment was loaded in PBS pH 
6.8 (7 ml) and bovine buccal mucosa of size 2.54 cm2 was mounted 
between the donor and receptor compartments. The set up was 
maintained under sink condition throughout the study period for 6 h 
at a constant temperature of 37±1 °C. A measured length of 2 cm2 of 
optimised (B4) was placed on the donor compartment and ex vivo 
permeation study was carried out. At definite intervals, 0.2 ml of 
sample was withdrawn from donor compartment with long needles 
and replaced with fresh 0.2 ml of PBS pH 6.8. The study was done for 
6 h and same experiment was repeated for 5 mg/ml of midazolam 
buccal solution (marketed formulation) and 4 mg/ml of control drug 
solution (drug in PBS pH 6.8) was done. After the dilution of samples 
suitably, samples are spectrophotometrically analysed by UV-VIS 
spectrophotometer at 229 nm and cumulative amount of drug 
permeated per cm2 were estimated and statistical interpretation 
using student T test was performed [48]. 
Steady-state flux determination 
The data obtained from ex vivo permeation were used to determine 
the permeation parameters like steady-state flux (J), enhancement 
ratio and statistical analysis by Student’s t-test was performed.  
Histopathological study 
The buccal mucosal membrane was isolated and prepared in a 
similar to that of ex vivo permeation study of lorazepam loaded 
buccal patch. The treated bovine buccal mucosa was subjected to 6h 
of ex vivo permeation study and histopathological examination were 
done to identify any visual damages occurring to the normal 
mucosal surface after treatment with the developed lorazepam 
loaded buccal patch [49]. 
Treatment of bovine buccal mucosa for histopathological study 
Histopathological study was done for three formulations. Previously 
treated bovine buccal mucosa was subjected to 5 h of ex vivo 
permeation study of optimised lorazepam loaded buccal patch (B4), 
midazolam buccal solution (marketed formulation), control drug 
solution (drug in PBS pH 6.8) and was compared with that of normal 
buccal mucosa which serves as normal control. The tissue taken 
after permeation study was initially fixed in 10% formalin solution. 
The preserved live tissue were equally cut into 5 µm containing 
sections and further stained with hematoxylin and eosin and 
analysed using light microscope [50]. 
Fourier transform infrared spectroscopy  
The FTIR spectrum of optimized lorazepam loaded buccal patch was 
compared with FTIR spectra of drug and excipients to check the 
compatibility among them [51].  
Scanning electron microscopy (SEM) 
The SEM image of optimised lorazepam loaded buccal patch (B4) was 
analysed by powdering the sample and further diluting with distilled 
water to examine under SEM (Joel jsm-64901a analytic SE) [52]. 
Stability study 
The optimised lorazepam loaded buccal patch (B4) was stored for 
45 d and was subjected to various stability studies within 
refrigerator (4±2 °C) and room temperature (29±2 °C) in triplicate. 
The samples were taken at frequent intervals and assessed for drug 
content release at various time intervals were calculated [53]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Solubility of Lorazepam 
Lorazepam is soluble in methanol, propanol and phosphate buffer saline 
(PBS pH 6.8) and is slightly soluble in distilled water and acetone.  
Melting point  
The melting point of the drug was determined by capillary method 
and was found to be 192-194 °C and was in accordance with the 
monograph IP. 
Partition coefficient 
Determination of Partition coefficient of the drug was carried out 
and was found to be 3.75. It shows that the drug is practically highly 
lipophilic and insoluble in water [54]. 
Fourier transform infrared (FTIR) spectroscopy  
The FTIR spectra of the drug Lorazepam and excipients, collagen 
and pectin were determined. 
In FTIR spectra of lorazepam a strong peak at 3549 cm-1 shows the 
presence of the hydroxy group. The most intense band present at 
1739 cm-1 is due to the presence of a carbonyl group (C=O). A peak 
at 673 cm-1 indicated presence of aromatic ring fig. 1A. FTIR spectra 
of collagen showed strong peak at 1650 cm-1. It indicated the 
presence of amide I carbonyl stretching. Amide II stretching is also 
present at 1560 cm−1. Three weak bonds are also present that 
represents amide III at 1245 cm-1 fig. 1B. 
FTIR spectra of pectin showed a broader peak at 3756 cm -1 
indicated the presence of hydroxyl functional group. A 
characteristic peak at 1161 cm -1 indicated the presence of C-O 
aluminum group fig. 1C. 
FTIR spectrum of optimized Lorazepam loaded buccal patch was 
determined by KBr pellet method. FTIR spectra of optimized 
Lorazepam loaded buccal patch showed a broad peak at 3612 cm-1 
indicated the presence of a hydroxy-functional group of Lorazepam, 
collagen, and pectin. A peak at 1691 cm-1 indicates the presence of 
ketone (carbonyl) functional group of Lorazepam. A peak at 1151 
cm-1 indicates the presence of C–O group of pectin fig. 1D.  
From the peaks, it was found that same peaks were retained as that 
of the peaks of Lorazepam and the excipients (collagen and pectin). 
No additional peaks were obtained. This confirmed the compatibility 
between the drug Lorazepam and the excipients. 
Formulation of lorazepam loaded buccal patch 
In this study, Lorazepam loaded buccal patches were prepared by 
solvent casting method using natural biodegradable polymers like 
collagen and pectin with olive oil as natural permeation enhancer and 
plasticizer. The concentration of olive oil was optimized. The patches 
were prepared with 0.25-1.25% and pectin 1.5%. The percentage of 
pectin was kept constant at 1.5%. As the concentration of collagen 
increased to 1.25 % the patches became harder and brittle in nature. 
When the patches were made with 0.50 to 1% collagen and 1.5% pectin, 
the patches possessed good flexibility and were easily removable from 
the Petri dish. But when the concentration of collagen was reduced to 
0.25%, the patch was difficult to remove from the Petri dish and was 
brittle in nature. All the patches prepared were translucent in nature. 
Nair et al. 




Fig. 1: A) FTIR spectrum of Lorazepam API, B) FTIR spectrum of collagen, C) FTIR spectrum of pectin, D) FTIR spectrum of optimized 




Fig. 2: A) Mean thickness B) Mean average weight, C) Mean surface pH, D) mean folding endurance, E) Mean % swelling, F) Mean % 
moisture absorbed, G) Mean drug content uniformity, (Values are expressed as mean±standard deviation, n=3) 
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Physico-chemical evaluation of prepared lorazepam loaded 
buccal patches 
Thickness uniformity of patches 
From the thickness studies it was found that the mean thickness of 
the patches increases with increase in the concentration of the 
collagen polymer from 0.25-1.25%, shown in fig. 2(a). The thickness 
of the patches was found to be satisfactory as the area of 
administration is the buccal region [54]. 
Uniformity of weight of patches 
The average weight of the patches varied from 114 mg±0.70 to 130 
mg±0.71 for B1-B5 as given in fig. 2(b). 
Folding endurance 
The folding endurance study confirmed that the patches did not 
undergo cracking even after it was folded for more than 100 times. 
The folding endurance values did not change much when a 
comparison was made between bare patches and the drug-loaded 
patches in fig. 2 (c) [55].  
Surface pH determination 
The surface pH of all the formulations B1-B5 was found to in the 
range 6.32±0.035-6.79±0.007 (fig. 2 (d)) indicating that the 
formulations were non-irritant to buccal mucosa [56]. 
Percentage swelling index 
The swelling index of the patches B1-B5 ranged from 12 %±0.70 to 
30 %±2.12 shown in fig. 2 (e). As the concentration of collagen 
increased more than an optimum concentration, the swelling 
property decreased. B4 formulation got maximum swelling index. 
The olive oil (plasticizer) also enhanced the swelling properties of 
the formulations [57]. 
Percentage moisture absorption 
The percentage moisture absorption of Lorazepam encapsulated 
patch was found to be between 5.15 %±0.07% to 5.02 %±0.14 as 
shown in fig. 2 (f). The lesser the percentage moisture absorption, 
the more the patches will be stable at humid conditions [58]. 
Drug content uniformity 
All the formulations exhibited good drug content. Among them, B4 
exhibited the highest drug content with 95.49±0.071% as shown in 
fig. 2 (g) [59]. 
In vitro mucoadhesion studies 
In vitro mucoadhesion time 
Mucoadhesion time taken for the Lorazepam loaded buccal patches 
to detach from the bovine buccal mucosa was noted. The 
mucoadhesion time taken for B4 formulation was found to be 
satisfactory when an optimum concentration of collagen was used, 
as shown in fig. 3(a). Mucoadhesion property of the patch is 
imparted by the presence of natural polymers like collagen and 
pectin. A higher value of mucoadhesion of optimized Lorazepam 
loaded buccal patch indicates that it can be attached to the bovine 
buccal mucosa for longer period of time with less risk of salivary 
clearance and provided a sustained effect for few hours[60]. 
In vitro mucoadhesion strength 
Mucoadhesion study was carried out for a longer time at the site of 
absorption to ensure that the formulation have the ability to adhere 
to the buccal mucosal membrane. The mucoadhesive character was 
exhibited due to the presence the two natural polymers collagen and 
pectin. The mucoadhesive strength of the optimized Lorazepam 
buccal patch (B4) was found to be optimum to produce its action 
shown in fig. 3(b). 
 
 
Fig. 3: A) In vitro mucoadhesion time, B) In vitro mucoadhesion strength, (Values are expressed as mean±standard deviation, n=3) 
 
 
Fig. 4: In vitro drug release of prepared B1-B5 formulations, (Values are expressed as mean±standard deviation, n=3) 
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In vitro drug release studies 
The in vitro drug release study gave an idea regarding the amount of 
the drug that is available for absorption into the systemic 
circulation. The release profile of drug predicts the in vivo behavior 
of the drug in the circulation. The pH of the buccal fluid lies between 
6.5-6.8. So the release studies were carried out using phosphate 
buffer solution of 6.8. The cumulative amount of drug released from 
each formulation v/s time curve was plotted. The cumulative 
percentage of drug released for all formulation varied from 
79.24±0.14% to 96.16±0.07 % at the end of 4 h. After 4 h, the patch 
lost its stability and integrity and was not suitable for further release 
study. The B4 formulation showed a maximum release of 96.16±0.07 
% when compared to other formulations, shown in fig. 4. The drug 
leached out from the surface of the patch into the phosphate buffer 
solution [61]. 
Kinetic model of in vitro drug release study 
The drug release profile of optimized Lorazepam loaded 
collagen/pectin buccal patch was attributed to different kinetic 
models like zero order, first order, Higuchi’s diffusion model and 
Korsmeyer peppas plot to interpret drug release by kinetic 
modeling. The release kinetics of the drug Lorazepam was found to 
be Zero-order and was best fitted with Higuchi diffusion model with 
the highest regression coefficient value, R2= 0.978 (fig. 5) [62]. 
 
Table 2: In vitro release model fitting data of optimized Lorazepam loaded buccal patch (B4) 
Zero order release plot First order release plot Higuchi plot Koresmeyer peppas plot Best fitted model 
R2 R2 R2 n R2 Higuchi Plot 
0.978 0.758 0.978 6.375 0.909 
 
Ex vivo permeation comparison study and steady-state flux 
determination 
For the optimized Lorazepam loaded buccal patch (B4) ex vivo 
permeation study was performed in franz diffusion cell using 
buccal mucosa of bovine. Each buccal mucosa of bovine resembled 
the human buccal mucosa hence the ex vivo studies were done 
using bovine buccal mucosa. Each bovine buccal mucosa was 
treated with optimized Lorazepam loaded buccal patch (B4), 
Midazolam buccal solution (marketed formulation) and control 
drug solution (drug in PBS pH 6.8). At a fixed time intervals from 
the receptor compartment 0.2 ml samples were withdrawn. These 
were analyzed and the cumulative drug permeated was plotted 
against time. The cumulative amount of drug permeated from the 
optimized Lorazepam loaded buccal patch (B4) was found to be 
3831.19 µg/cm2 at the end of 4 h, from Midazolam buccal solution 
(marketed formulation) was found to be 1724.12 µg/cm2 and from 
control drug solution (drug in PBS pH 6.8) was found to be 895.43 
µg/cm2 at the end of 4 h. This means that the amount of drug 
permeated from optimized Lorazepam loaded buccal patch (B4) 
formulation was higher compared to other formulation with an 
enhancement ratio of 4.88 (fig. 6). Similarly the enhancement ratio 
of Midazolam buccal solution (marketed formulation) was found 
to be 2.23 [63]. 
  
 
Fig. 6: Ex vivo permeation comparison study of optimized Lorazepam loaded buccal patch (B4) and the Midazolam buccal solution 
(marketed formulation) with control drug solution (drug in PBS pH 6.8), (Values are expressed as mean±standard deviation, n=3) 
 
Table 3: Ex vivo permeation study of optimized Lorazepam loaded buccal patch (B4), Midazoalm buccal solution (marketed formulation), 
and control drug solution (drug in PBS pH 6.8) 
S. No. Parameters Optimized Lorazepam loaded 
buccal patch (B4) 
Midazolam buccal solution 
(marketed formulation) 
Control drug solution (drug 
in PBS pH 6.8) 
1 Steady state flux–J 
(µg/cm²/h) 
12.52±0.02 5.732±0.01 2.563±0.03 
2 Enhancement ratio 4.88 2.23 - 
(Values are expressed as mean±standard deviation, n=3) 
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From the data obtained from the ex vivo permeation study, the slope 
gives the steady-state flux of the three formulations as shown in table 3. 
The steady-state flux value was higher for the optimized Lorazepam 
loaded buccal patch 12.52±0.02 µg/cm²/hr than the Midazolam 
buccal solution (marketed formulation) 5.732±0.01 μg/cm²/hr and 
the control drug solution (drug in PBS pH 6.8) 2.563±0.03 μg/cm²/h. 
The enhancement ratio was obtained by the ratio of the steady-state 
flux values optimized Lorazepam loaded the buccal patch and the 
Midazolam buccal solution (marketed formulation) with that of the 
control drug solution [63, 64]. The enhancement ratio of the 
optimized Lorazepam loaded buccal patch was found to be 4.88 and 
that of Midazolam buccal solution (marketed formulation) was 
found to be 2.23 (fig. 7). 
 
 
Fig. 7: Comparison of the steady state flux values of optimized Lorazepam loaded buccal patch, the midazolam buccal solution (marketed 
formulation) and the control drug solution 
 
Statistical analysis by student’s t-test 
The statistical analysis by Student’s t-test were performed for the steady-
state flux values of the optimized Lorazepam loaded buccal patch, the 
Midazolam buccal solution (marketed formulation) and the control drug 
solution (drug in PS pH 6.8). The statistical analysis by Student’s t-test 
revealed that there was significant difference in the steady-state flux 
value of the optimized Lorazepam loaded buccal patch (B4) and the 
Midazolam buccal solution (marketed formulation) with that of the 
control drug solution (drug in PBS pH 6.8), where (P<0.05) thus very 
significant. Hence the difference was statistically significant [65]. 
Histopathological studies 
The bovine buccal mucosa, which was subjected to ex vivo 
permeation studies were assessed for histopathological studies. The 
fig. 8[B, C, D] showed that there were no significant changes 
observed in the histological pattern of the mucosa treated with 
optimized Lorazepam loaded buccal patch, Midazolam buccal 
solution (marketed formulation) and control drug solution 
(Lorazepam in PBS pH 6.8) as compared with the normal buccal 
mucosa shown in fig. 8 [A]. Hence, Lorazepam loaded buccal patch 
did not cause any irritation and was safe for the buccal application. 
 
 
Fig. 8: Histopathological studies of the buccal mucosa A) Normal buccal mucosa, B) Buccal mucosa with optimized Lorazepam loaded 
buccal patch (B4), C) Buccal mucosa treated with Midazolam buccal solution (marketed formulation), D) Buccal mucosa treated with 
control solution (Lorazepam in PBS pH 6.8) 
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Scanning electron microscopy (SEM) 
The SEM study was carried out for optimized Lorazepam loaded 
buccal patch (B4) in order to examine the morphology of the buccal 
patch. The surface morphology of Lorazepam incorporated 
collagen/pecin buccal patch, indicates that surface is smooth and 
drug is found dispersed within the matrix shown im fig. 9 [66]. 
Stability study 
The stability study of the optimized Lorazepam loaded buccal patch 
(B4) was carried out for 45 d at room temperature (30±2 °C) and at 
refrigerator temperature (4±2 °C) and its physical changes like 
colour, flexibility, texture, drug content and % drug release was 
estimated at an interval of one week [67]. The physical appearance 
of the patch was retained that it did not show any change on 
comparing with the freshly prepared patch at refrigeration and 
room temperature. The drug content and cumulative percentage 
drug release were determined for the patches at 7th, 15th, 30th, 45th 
day (fig. 10 and fig. 11). The results of the study indicated that there 
were no significant changes observed in room temperature and 
refrigerated temperature. The stability study revealed that the 
optimized Lorazepam loaded buccal patch B4 of 1% collagen 
concentration remained stable at room temperature and 
refrigerated temperature [68]. 
 
 
Fig. 9: SEM image of Lorazepam incorporated buccal patch 
 
 
Fig. 11: A) Stability data showing the mean drug content of optimized Lorazepam loaded buccal patch (B4) formulation, B) Stability data 
showing the cumulative % drug release of optimized Lorazepam loaded bucccal patch (B4) formulation, (values are expressed as 
mean±Standard deviation, n=3) 
 
CONCLUSION 
Epilepsy is a chronic neurologic disorder that causes unprovoked 
recurrent seizures. Even though there have been different modes of 
drug delivery systems developed to treat the epileptic seizures, none 
of them proved to be fully effective. Buccal patches, as a potential 
drug delivery systems, gained relevance in the pharmaceutical area 
as a novel, patient-friendly, convenient and excellent forms of 
accessible products. Lorazepam loaded buccal patches were 
prepared by solvent casting method using a blend of biodegradable, 
biocompatible natural polymers like pectin (hydrophilic) and 
collagen (lipophilic) with olive oil as permeation enhancer and 
plasticizer. The prepared unidirectional buccal patches of 
Lorazepam provided a maximum drug release within specified 
mucoadhesion period and possessed a higher permeation 
coefficient/flux and enhancement ratio as compared to the 
Midazolam buccal solution (marketed formulation) and control drug 
solution (drug in PBS pH 6.8). Thus the formulated Lorazepam 
loaded collagen/pectin buccal patch was found to be an efficient and 
stable route for the buccal delivery of Lorazepam in treating acute 
epileptic seizures which could be further explored scientifically.  
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